tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

CANF Stock Latest News

D. Boral says Can-Fite’s namodenoson may represent liver cancer ‘paradigm shift’
The FlyD. Boral says Can-Fite’s namodenoson may represent liver cancer ‘paradigm shift’
19d ago
CANF
Can-Fite’s Namodenoson to be Highlighted for Liver Protection at ASCO Symposium
PremiumCompany Announcements
Can-Fite’s Namodenoson to be Highlighted for Liver Protection at ASCO Symposium
20d ago
6K
CANF
Can-Fite BioPharma announces presentation on namodenoson
PremiumThe Fly
Can-Fite BioPharma announces presentation on namodenoson
20d ago
CANF
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
1M ago
ALT
VIR
Can-Fite BioPharma’s Namodenoson Shows Promising Cancer Results
PremiumCompany Announcements
Can-Fite BioPharma’s Namodenoson Shows Promising Cancer Results
2M ago
6K
CANF
Can-Fite announces 8 year survival for patient in Phase 2 Liver Cancer study
PremiumThe FlyCan-Fite announces 8 year survival for patient in Phase 2 Liver Cancer study
2M ago
CANF
CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CANF
Can-Fite BioPharma Advances in Pancreatic Cancer Trial
Premium
Company Announcements
Can-Fite BioPharma Advances in Pancreatic Cancer Trial
2M ago
6K
CANF
Can-Fite BioPharma doses first patient in Phase IIa trial
PremiumThe Fly
Can-Fite BioPharma doses first patient in Phase IIa trial
2M ago
CANF
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
PremiumCompany Announcements
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
3M ago
6K
CANF
Can-Fite BioPharma announces an update related to IP status of Namodenoson
PremiumThe Fly
Can-Fite BioPharma announces an update related to IP status of Namodenoson
3M ago
CANF
Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix
PremiumCompany Announcements
Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix
3M ago
6K
CANF
Can-Fite BioPharma reports results from osteoarthritis clinical study in dogs
PremiumThe FlyCan-Fite BioPharma reports results from osteoarthritis clinical study in dogs
3M ago
CANF
Can-Fite’s Namodenoson Gains FDA Orphan Status
Premium
Company Announcements
Can-Fite’s Namodenoson Gains FDA Orphan Status
3M ago
6K
CANF
Can-Fite BioPharma announces FDA granted ODD for Namodenoson
Premium
The Fly
Can-Fite BioPharma announces FDA granted ODD for Namodenoson
3M ago
CANF
Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status
PremiumThe Fly
Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status
3M ago
CANF
Can-Fite BioPharma’s Lucrative Veterinary Licensing Deal
PremiumCompany Announcements
Can-Fite BioPharma’s Lucrative Veterinary Licensing Deal
4M ago
6K
CANF
Can-Fite BioPharma signs development, commercialization agreement with Vetbiolix
PremiumThe Fly
Can-Fite BioPharma signs development, commercialization agreement with Vetbiolix
4M ago
CANF
Can-Fite Advances Pancreatic Cancer Drug Trial
PremiumCompany Announcements
Can-Fite Advances Pancreatic Cancer Drug Trial
4M ago
6K
CANF
Can-Fite received approval from Israeli MoH to conduct Phase IIa trial
PremiumThe FlyCan-Fite received approval from Israeli MoH to conduct Phase IIa trial
4M ago
CANF
Can-Fite BioPharma Launches $9M ADS Offering
Premium
Company Announcements
Can-Fite BioPharma Launches $9M ADS Offering
5M ago
6K
CANF
Can-Fite BioPharma files to sell 1.77B ordinary shares for holders
Premium
The Fly
Can-Fite BioPharma files to sell 1.77B ordinary shares for holders
5M ago
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >